To include your compound in the COVID-19 Resource Center, submit it here.

Priority Review for Imfinzi in NSCLC that has not progressed

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted and granted Priority Review

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE